(R)-1-(3,5-Difluorophenyl)ethanamine is primarily utilized in the pharmaceutical industry as a chiral building block for the synthesis of various active pharmaceutical ingredients (APIs). Its enantiomeric purity makes it valuable in the development of drugs that require specific stereochemistry for efficacy, particularly in central nervous system (CNS) therapeutics and enzyme inhibitors. Additionally, it serves as an intermediate in the production of compounds targeting neurological disorders, such as Alzheimer's disease and depression, due to its ability to interact with specific biological receptors. Its fluorinated aromatic ring also enhances metabolic stability, making it a preferred choice in the design of drug candidates with improved pharmacokinetic properties.